Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
27069189
PII: 36/4/1973
Knihovny.cz E-resources
- Keywords
- Cancer, biomarkers, bone metastasis, multiplex technology, scintigraphy,
- MeSH
- Adipokines blood MeSH
- Cytokine TWEAK MeSH
- Isoenzymes blood MeSH
- Colorectal Neoplasms pathology MeSH
- Tartrate-Resistant Acid Phosphatase MeSH
- Acid Phosphatase blood MeSH
- Lectins blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Biomarkers, Tumor blood MeSH
- Bone Neoplasms blood secondary MeSH
- Lung Neoplasms pathology MeSH
- Prostatic Neoplasms pathology MeSH
- Breast Neoplasms pathology MeSH
- Osteonectin blood MeSH
- Pilot Projects MeSH
- Chitinase-3-Like Protein 1 MeSH
- Growth Differentiation Factor 15 blood MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Tumor Necrosis Factors blood MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adipokines MeSH
- CHI3L1 protein, human MeSH Browser
- Cytokine TWEAK MeSH
- GDF15 protein, human MeSH Browser
- Isoenzymes MeSH
- Tartrate-Resistant Acid Phosphatase MeSH
- Acid Phosphatase MeSH
- Lectins MeSH
- Biomarkers, Tumor MeSH
- Osteonectin MeSH
- Chitinase-3-Like Protein 1 MeSH
- Growth Differentiation Factor 15 MeSH
- TNFSF12 protein, human MeSH Browser
- Tumor Necrosis Factors MeSH
BACKGROUND: Bone metastases develop in several malignancies (multiple myeloma, breast, prostate and lung carcinoma) and cause several complications. The aim of this study was to search for new biomarkers to use in monitoring of bone metastatic disease with the use of xMAP technology. PATIENTS AND METHODS: We assessed 62 oncological patients: 23 with no bone metastases, 28 with metastatic disease not having undergone therapy and 11 with metastatic disease treated by denosumab. Serum levels of dickkopf-related protein 1 (DKK1), growth differentiation factor-15 (GDF15), neuron-specific enolase (NSE), osteoprotegerin (OPG), osteonectin, periostin, tartrate-resistant acid phosphatase (TRAP5), tumor necrosis factor related weak inducer of apoptosis (TWEAK), chitinase-3-like protein 1 (YKL40), carboxy-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (PINP) were measured in each sample. RESULTS: The following biomarkers were observed to have significantly higher levels in the groups of patients with metastases in comparison to metastasis-free patients: GDF15 (p<0.0001), osteonectin (p=0.0311), TRAP5 (p<0.0046), TWEAK (p<0.0343) and YKL40 (p<0.0034). The changes in DKK1, NSE, OPG and periostin were not significant. CONCLUSION: We identified five new biomarkers: GDF15, osteonectin, TRAP5, TWEAK, and YKL40 as being promising markers for monitoring bone metastases.
